Small Molecule Metabolites in Drug Discovery and Development | An ISSX 2023 Virtual Workshop Event

Small Molecule Metabolites in Drug Discovery and Development | An ISSX 2023 Virtual Workshop Event

  • Register
    • Non-member - $400
    • Member - $300
    • Student - $125
    • Premier - Free!

This workshop is organized through the efforts of the ISSX Biotransformation Mechanisms and Pathways Focus Group and is chaired by Carley Heck of Pfizer and Valerie Kramlinger of Vanderbilt University.

This virtual workshop will focus on the impact of small organic molecule metabolism science on both drug discovery and drug development. This three day workshop will dissect the types of in vitro and in vivo drug metabolism studies conducted to support the drug discovery-development pipeline, including the experimental and analytical techniques used and the impact of the data generated. Some of the exciting topics to be covered are: the importance of drug metabolites, analytical techniques of metabolite ID, prediction of human circulating metabolite profiles, metabolite biosynthesis, human ADME study strategies and impact, and both the pharmaceutical industry and regulatory perspectives on the value of human ADME studies and drug metabolism science. Each session of this workshop will feature 4-5 expert speakers, a daily panel discussion, and poster sessions; the latter will be selected from the pool of abstracts from the students and industry attendees.

The workshop includes access to all presentation slides and recordings.

  • Contains 1 Component(s)

    This virtual workshop will focus on the impact of small organic molecule metabolism science on both drug discovery and drug development.

    Chairs: Aaron Teitelbaum, Bingming Chen, Carley Heck, and Matthew Albertolle

    Why Drug Metabolites Can be Important; Examples of Active and Toxic Metabolites 

    image



    Rheem Totah, University of Washington, Seattle, Washington, USA


    Modern Method of Metabolite ID: Part 1. HRMS: Instrumentation, Strategies

    image


    Mark Cancilla, Merck & Co., Inc, West Point, Pennsylvania, USA



    Modern Method of Metabolite ID: Part 2. 1D and 2D NMR

    image

    Gregory Walker, Pfizer, Groton, Connecticut, USA



    Predicting Metabolite Levels From in vitro Data

    image  


    Ernie Callegari, Pfizer, Groton, Connecticut, USA




    Accessing Metabolites of Various Types – Biosynthesis, Isolation Methods 

    image


    Liz Gillam, University of Queensland 


    Roundtable Discussion with Speakers





  • Contains 1 Component(s)

    This virtual workshop will focus on the impact of small organic molecule metabolism science on both drug discovery and drug development.

    Chairs: Aaron Teitelbaum, Bingming Chen, Carley Heck, and Matthew Albertolle

    The Human ADME Study: Comparison of Various Strategies and Technical Approaches

    image


    Chandra Prakash, Agios




    Accelerator Mass Spectrometry for the Support of Microtracer Studies @ Boehringer-Ingelheim, Technical Aspects of AMS' Deep Dive on How AMS Actually Works

    image


     Stefan Blech, Boehringer Ingelheim



    image



    Ralf Laux, Boehringer Ingelheim



    How to Deal with Metabolites from Human ADME: Part 1. MIST 

    image


    Yuexia Liang, Merck



    Assessing Metabolite Contribution to Target Activity and DDI 

    image


    Sheila Peters, Boehringer Ingelheim




    Roundtable Discussion with Speakers

  • Contains 1 Component(s)

    This virtual workshop will focus on the impact of small organic molecule metabolism science on both drug discovery and drug development.

    Chairs: Faye Vazvaei-Smith, Wenkui Li, Carley Heck, and Scott Obach

    Industry Perspective on the Value of ADME Studies and Drug Metabolites

    image


    Douglas Spracklin, Pfizer




    Drug Metabolites and Their Roles in Drug-drug Interactions

    image

     

    Xinning Yang, U.S. Food and Drug Administration



    Vignette 1

    image


    Simone Schadt,
     Roche




    image



    Kenichi Umehara, Roche




    Vignette 2 

    image


    Sekhar Surapaneni,
    Bristol Myers Squibb




    Roundtable Discussion with Speakers